Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01764633
First received: January 8, 2013
Last updated: November 22, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2016
  Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)